The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > 4-S-(propionic acid)sulfidocyclophosphamide

4-S-(propionic acid)sulfidocyclophosphamide

4-S-(Propionic Acid)Sulfidocyclophosphamide is a alkylating agent and antimetabolite chemotherapeutic compound.
It is used in the treatment of various cancers, including leukemia and lymphoma.
The compound works by disrupting DNA replication and cell division, leading to cell death.
Careful consideration of research protocols and product selection is crucial for optimizing the efficacy and reproducbility of 4-S-(Propionic Acid)Sulfidocyclophosphamide studies.
PubCompare.ai's AI-driven platform can help researchers identify the best products and protocols from literature, preprints, and patents to enhance the accuracy and reliability of their 4-S-(Propionic Acid)Sulfidocyclophosphamide research.

Most cited protocols related to «4-S-(propionic acid)sulfidocyclophosphamide»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
4-S-(propionic acid)sulfidocyclophosphamide Atrium, Left Body Surface Area Catheterizations, Cardiac Diastole ECHO protocol High Blood Pressures Left Ventricles Patients Pulmonary Capillary Wedge Pressure Pulmonary Hypertension Veins Veins, Pulmonary
The PEG–PAsp(DET) block copolymer and PAsp(DET) homo polymer were synthesized as reported previously [30] (link). The PEG used in this study had a molecular weight (MW) of 12,000. By 1H-NMR analyses, the polymerization degree of the PAsp(DET) portion was determined to be 57 for PEG–PAsp(DET) and 52 for PAsp(DET). Linear polyethyleneimine (LPEI) (ExGen 500 in vivo; MW = 22 kDa) was purchased from MBI Fermentas (Burlington, ON, Canada). For the preparation of the polyplex nanomicelle, PEG-PAsp(DET) polymer and nucleic acids (mRNA or DNA) was separately dissolved in 10 mM Hepes buffer. At this stage, the concentration of nucleic acid was set to 300 µg/ml, and that of PEG-PAsp(DET) was adjusted to obtain the ratio of amino groups in polymers to phosphate in mRNA or DNA (N/P ratio) to be 8. The solutions of PEG-PAsp(DET) polymer and nucleic acids were mixed by the volume ratio of 1∶2, resulting in the polyplex nanomicelle solution containing 200 µg/ml of nucleic acids. PAsp(DET)-based mRNA carrier (N/P = 8) was prepared similarly as the polyplex nanomicelle. LPEI-based mRNA carrier was prepared following the manufacture's protocol at N/P ratio of 6. Lipofectamine 2000 (Invitrogen) and mRNA were mixed at the ratio indicated in the manufacturer's protocol. Final concentrations of nucleic acids (mRNA and pDNA) were adjusted to 200 µg/ml for all the samples.
Full text: Click here
Publication 2013
1H NMR 4-S-(propionic acid)sulfidocyclophosphamide Buffers Cardiac Arrest HEPES Homo lipofectamine 2000 Nucleic Acids Phosphates Polyethyleneimine Polymerization Polymers RNA, Messenger
Plasma erythropoietin concentration was measured immediately prior to each acute hypoxic challenge. The apparatus and techniques used in the acute hypoxic challenges have been extensively validated and described in detail previously (Balanos et al. 2005 (link); Smith et al. 2006 (link)). Challenges were conducted with the subject reclining in the left lateral position and breathing through a mouthpiece. Gas control was achieved by means of dynamic end-tidal forcing (Robbins et al. 1982 (link)). For each challenge an initial 5 min of euoxia ( of 100 mmHg) preceded a period of 20 min of isocapnic hypoxia ( 50 mmHg). This was followed by a final 10 min of euoxia. End-tidal partial pressure of carbon dioxide was maintained close to each subject's baseline value. A Sonos 5500 echocardiography machine (2–4 MHz transducer; Hewlett-Packard, Boston, MA, USA) was used to monitor PASP continuously. Using a standard Doppler technique, the maximum systolic pressure gradient across the tricuspid valve was determined and PASP was calculated using the modified Bernoulli equation and an estimated right atrial pressure of 5 mmHg (Swenson et al. 2002 (link); Smith et al. 2006 (link)). Heart rate and ventilation were recorded, and cardiac output was determined echocardiographically every 2 min (Howson et al. 1986 ; Balanos et al. 2005 (link)).
Publication 2008
4-S-(propionic acid)sulfidocyclophosphamide Carbon dioxide Cardiac Output Echocardiography Erythropoietin Hypoxia Partial Pressure Plasma Rate, Heart Systolic Pressure Transducers Valves, Tricuspid
The primary endpoint was the change in peak VO2 after 24 weeks of therapy. A number of subgroup analyses were pre-specified. Secondary endpoints included a composite hierarchical-rank clinical score where patients were ranked (range 1-N with data) based on time-to-death (tier 1), time-to-hospitalization for cardiovascular or cardiorenal causes (tier 2), and change in MLHFQ from baseline (tier 3) for patients alive without cardiovascular or cardiorenal hospitalization after 24 weeks of therapy.10 (link) As 189 patients had data for this endpoint, the anchor value (mean value in each group indicating no treatment effect) was 95. Other secondary endpoints included change in 6MWD at 24 weeks and change in peak VO2 and 6MWD after 12 weeks of therapy. Peak sildenafil levels at 12 and 24 weeks and coinciding plasma cGMP levels at 24 weeks were assessed. Using other pre-specified endpoints, we assessed the effect of PDE-5 inhibition on LV structure and vascular function by CMR, Doppler-estimated diastolic function parameters and pulmonary artery systolic pressure (PASP), and biomarkers that reflect renal and neuroendocrine function, oxidative stress and collagen metabolism.
The percent-predicted peak VO2, 6MWD, and the presence of chronotropic incompetence and LVH were calculated using published criteria (e-Methods).11 (link)–14 (link)
Publication 2013
4-S-(propionic acid)sulfidocyclophosphamide Biological Markers Blood Physiological Phenomena Cardiovascular System Collagen Cyclic GMP Diastole Hospitalization Kidney Metabolism Neurosecretory Systems Oxidative Stress Patients Plasma Psychological Inhibition Pulmonary Artery Sildenafil Systolic Pressure Therapeutics
We applied our original algorithm OncoFinder [12 ] for the functional annotation of the primary expression data and for the calculation of the PAS scores. The extracted raw microarray expression data were quantile normalized according to [44 (link)]. Our approach to the transcriptome-wide gene expression analysis applies processing of these results with the signalome knowledge base developed by SABiosciences (http://www.sabiosciences.com/pathwaycentral.php). The algorithm utilizes a scheme that takes into account the overall impact of each gene product in the signaling pathway but ignores its position in the pathway graph. The formula used to calculate the pathway activation strength (PAS) for a given sample and a given pathway p is as follows:
PASp=nARRnpBTIFnlg(CNRn)
Here the case-to-normal ratio, CNRn, is the ratio of expression levels for a gene n in the sample under investigation to the same average value for the control group of samples. The Boolean flag of BTIF (beyond tolerance interval flag) equals zero when the CNR value has passed simultaneously the two criteria that demark the significantly perturbed expression level from essentially normal. The first criterion is the expression level for the sample lies within the tolerance interval, where p > 0.05. The second criterion is the discrete value of ARR (activator/repressor role) equals to the following fixed values: −1, when the gene/protein n is a repressor of pathway excitation; 1, if the gene/protein n is an activator of pathway excitation; 0, when the gene/protein n can be both an activator and a repressor of the pathway; 0.5 and −0.5, respectively, if the gene/protein n is rather an activator or repressor of the signaling pathway p, respectively. The results for the 82 pathways were obtained for each sample (listed in the Supplementary dataset 2). The area-under-curve (AUC) values were calculated according to [28 ]. Statistical tests were done using the R software package.
Full text: Click here
Publication 2014
4-S-(propionic acid)sulfidocyclophosphamide Gene Expression Profiling Genes Immune Tolerance Microarray Analysis nucleoprotein, Measles virus Proteins Signal Transduction Pathways Transcriptome

Most recents protocols related to «4-S-(propionic acid)sulfidocyclophosphamide»

All echocardiograms were performed and interpreted by level-III-trained sonographers and echocardiologists. Echo systems used included Vivid 3 Premium and Vivid E95 (General Electric, Milwaukee, WN, USA), Agilent 5500 (Agilent, Santa Clara, CA, USA), HP 77020 (Hewlett Packard, Andover, MA, USA), and IE33 and EPIQ (Philips, Amsterdam, The Netherlands). Diagnostic measurements and conclusions made at each study were based on criteria set forth by the relevant American Society of Echocardiography guidelines [8 (link),9 (link)]. Mitral valve assessment incorporated standard multiple views. Regurgitation severity was determined based on the integration of qualitative and semiquantitative measures, whenever possible. A diagnosis of degenerative mitral valve (MV) disease required the visualization of leaflet prolapse, signified by a ≥2 mm atrial displacement of the leaflet tip from the mitral annular level at end-systole. Pulmonary veins (PVs) were assessed bilaterally. After verification of tangentiality by color Doppler, the flow at each PV was sampled by a pulsed-wave (PW) Doppler beam placed within 1 cm of the PV ostia. Normal PVFP was defined by a peak systolic (S) velocity to peak diastolic (D) velocity ratio of 1 and above (Figure 1); conversely, PVFP reversal was characterized by an S to D ratio of below zero. Blunted PVFP, considered a form of non-reversed PVFP, was further identified by an S to D ratio between zero and below 1. Overall flow was determined according to the lowest S to D ratio observed. Pulmonary arterial systolic pressure (PASP) assessment was based on the peak systolic pressure gradient measured across the tricuspid valve and the estimated right atrial pressure (RAP) using the diameter and respiratory collapsibility of the inferior vena cava (IVC), both during the TTE part of each study. Global right ventricular (RV) function was evaluated qualitatively. All reports were blindly scrutinized for integrity by two physicians (A.Shechter and I.Y.).
Full text: Click here
Publication 2023
4-S-(propionic acid)sulfidocyclophosphamide Diagnosis Diastole Echocardiography ECHO protocol Electricity Heart Atrium Mitral Valve Physicians Prolapse Pulmonary Artery Respiratory Rate Systole Systolic Pressure Ultrasonography, Doppler, Pulsed Valves, Tricuspid Veins, Pulmonary Vena Cavas, Inferior Ventricular Function, Right
Targeted alteration of putative KojR DNA-binding sites was carried out using the established genome-editing CRISPR/Cas9 technology [27 (link)]. pAf-CRISPR-yA (Addgene plasmid #191015) was the template for making DNA fragments that encoded single guide RNAs (sgRNAs) to target motif sequences. The PCR fragments were cloned into the PstI and KpnI sites of pAsp-AMA-gpdA-ptr (Addgene plasmid #191016) to give the resulting gene-targeting vectors. The target sequences in kojA and kojT for the CRISPR/Cas9 complexes were GGTGGAATGAGCGGCAAAGTCGG and AAGCCATTCAGCGGCTAAGTCGG, respectively (motif sequences are underlined). To construct a sgRNA expression cassette, two target-specific DNA fragments were first generated by PCR with primer sets of U6-F-P/kojA_R or kojT_R and kojA_F or kojT_F/U6-R-K, respectively (Table S1). To this end, 40 pmol of each primer and 2 ng template were added to 20 μL of AccuPrime™ SuperMix (Invitrogen) and subjected to thirty cycles of PCR, which consisted of denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s and extension at 72 °C for 1.0 min. The two PCR fragments, without further purification, were directly fused and amplified by another round of PCR using primers U6-F-P and U6-R-K. The annealing time was set for 2 min. The resulting fragment, after being cut with PstI and KpnI, was cloned to give a final vector. Gene-targeting vectors were transformed into the wild-type A. flavus CA14 recipient as previously described [21 (link)]. Selected primary pyrithiamine-resistant transformants were transferred onto KAM plates and grown at 30 °C for two to three days for direct PCR and sequencing analyses to confirm indel defects in the targeted kojA and kojT genes.
Full text: Click here
Publication 2023
4-S-(propionic acid)sulfidocyclophosphamide Binding Sites Cloning Vectors Clustered Regularly Interspaced Short Palindromic Repeats Genes Genetic Vectors INDEL Mutation Mutagenesis, Site-Directed Oligonucleotide Primers Plasmids Pyrithiamine RNA, Single Guide Sequence Analysis
Extraction of total protein from the muscle samples was performed as described previously [28 (link)]. PASP lysis buffer (8 M Urea, 100 mM NH4HCO3, pH 8) was used to lyse the samples followed by ultrasonication on ice for 5 min. The lysate was centrifuged for 15 min at a rate of 12,000× g and 4 °C. The supernatant was first reduced with 10 mM DL-Dithiothreitol (DTT) at 56 °C for 1 h and then alkylated with iodoacetamide (IAM) at room temperature in the darkness for 1 h. After that, the samples were resuspended in precooled acetone (4 times the volume of the samples), incubated for a minimum of 2 h at −20 °C, and centrifuged for 15 min at a rate of 12,000× g and 4 °C to obtain the precipitate. The precipitate was first resuspended in 1 mL of pre-cooled acetone and then centrifuged for 15 min at 12,000× g and 4 °C. The resulting pellet was dissolved in dissolution buffer (100 mM TEAB, 8 M Urea, pH 8.5).
Protein quantification was performed with a Bradford protein quantitative kit (Beyotime Biotechnology, Shanghai, China), following the manufacturer’s guidelines. Protein integrity assays were performed by subjecting 20 µg of each protein sample to SDS–PAGE (12%) for 20 min at 80 V, and 50 min at 120 V. The gel was visualized after staining it with coomassie brilliant blue R-250. All samples were satisfactory for protein integrity and were allowed to proceed to subsequent experiments.
Full text: Click here
Publication 2023
4-S-(propionic acid)sulfidocyclophosphamide Acetone Biological Assay Buffers Coomassie brilliant blue R Darkness Dithiothreitol Iodoacetamide Muscle Tissue Proteins SDS-PAGE Staphylococcal Protein A triethylammonium bicarbonate Urea
Data on Striga emergence count, ear rot, stalk and root lodging were transformed as [log (counts+1)] to reduce the heterogeneity of variances. The ANOVA for the 150 hybrids generated using the NCD II pooled over sets for each research condition [15 (link)] and across the stress conditions was carried out using the version 9.4 of SAS [33 ]. The genotypic component of the source of variation was partitioned into the variation due to males (sets), females (sets), and female × male (sets) interaction. The F-tests for male (sets), female (sets) and male × female (sets) mean squares were performed using male (sets) × environment, female (sets) × environment and male × female (sets) × environment mean squares, respectively. The mean squares attributable to environment × female × male (sets) were tested using the pooled error mean squares.
The following general linear model was used for the NCD II mating design:
Xijkl=μ+mi+fi+(mf)ij+pijk+Il+εijkl
where Xijkl = the observed value of the progeny of the ith male crossed with jth female in the kth replication; μ = the overall population mean; mi = effect of the ith female; fj = the effect of the jth male mated to the ith female; (mf)ij = the interaction effect between the ithfemale and the jth male; pijk = the effect of the kth progeny from the cross between ith female and jth male; rl = the effect of the lth replication; εijkl = the experimental error. The general combining ability (GCA) effects for male and female within sets (GCAm and GCAf) and specific combining ability (SCA) for each trait were estimated according to Kearsey and Pooni [34 ] as shown below:
GCAm=Xmμ
GCAf=Xfμ
where, GCAm and GCAf = General combining ability effects of male and female parents respectively; Xm and Xf = Average performance of a line when used as a male and female in crosses, respectively and μ = Overall mean of crosses in the set.
Standard errors (SE) for testing significance of GCAm and GCAf estimates, for traits of genotype, were computed from the mean squares of GCAm × environment and GCAf × environment, respectively as follows:
SEforGCAm=MSm×e/(f×e×r)
SEforGCAf=MSf×e/(m×e×r)
where, MSm × e and MSf × e were the mean squares of the interaction between male and environment as well as female × environment, respectively; f, m, r, and e were the number of females, males, replicates, and environments, respectively.
A multiple trait base index (MI) that integrated grain yield with the number of emerged Striga plants, Striga damage rating, plant and ear aspects, delayed leaf senescence, anthesis-silking interval and number of ears per plant was used to select the best performing hybrids across optimal, Striga and low-N conditions [5 (link)]. The means, adjusted for block effects of each genotype for each measured variable was standardized to minimize the effects of the different scales. A positive multiple trait base index value therefore indicated tolerance/resistance of the genotype to both Striga and low-N, while negative values indicated susceptibility to the stresses. The multiple trait base index was computed as follows:
MI = (2 × YLD) + EPP–EASP–PASP—STGR–RAT1 –RAT2 –(0.5 × C01)–(0.5 × C02)
On the other hand, the base indices for Striga and Low-N were computed as STRBI = 2.0 YLD + 1.0 EPP–(RAT1 + RAT2)– 0.5 (C01 + C02) and LNBI = 2.0 YLD + EPP–STGR–ASI—PASP–EASP, respectively to select superior hybrids under the respective stress conditions.
Where: MI = Multiple trait base index
STRBI = Base index for StrigaLNBI = Base index for Low-N
YLD = grain yield across research conditions
EPP = number of ears per plant across research conditions
EASP = Ear aspect across research conditions
PASP = Plant aspect across low-N and optimal conditions
STGR = Stay green characteristic across low-N conditions
RAT1 and RAT2 = Striga damage rating at 8 and 10 WAP across Striga infested conditions
C01 and C02 = Number of emerged Striga plants at 8 and 10 WAP across Striga -infested conditions.
Full text: Click here
Publication 2023
(2-formylethyl)phenylphosphinic acid ethyl ester 4-S-(propionic acid)sulfidocyclophosphamide Boys Cereals DNA Replication Females Genetic Heterogeneity Genotype Hybrids Immune Tolerance Leaf Senescence Males neuro-oncological ventral antigen 2, human Parent Plant Roots Plants Stalking Stress Disorders, Traumatic Striga Susceptibility, Disease
All echocardiographic measurements were performed by two expert cardiologists (AP and GR) according to the instructions provided by the American Society of Echocardiography [16 (link)]. Therefore, principal measurements were recorded and independently reviewed by two distinct physicians. The systolic and diastolic volumes and ejection fraction were determined using apical two and four chamber views by Simpson biplane formula. We evaluated three consecutive cardiac cycles to obtain average pulsed Doppler transmitral flow velocity during early diastole velocity (E wave) and late diastole velocity (A wave) ratio (E/A) and the deceleration time (DT) of E. Placing the cursor laterally and medially at the mitral annulus level, we estimated mitral annulus movement by apical four-chamber tissue Doppler imaging (TDI). We obtained the recordings of systolic peak velocity (S’), early diastolic myocardial velocity (e’) and atrial systole velocity (A’), for three consecutive cardiac cycles. We calculated the ratio of peak early diastolic filling velocity and septal tissue Doppler early diastolic velocity (E/e’). In patients with atrial fibrillation, we measured E/e1 ratio and DT values. E/e’ > 15 was considered an index of elevated left ventricular (LV) filling pressure and severe diastolic dysfunction [17 (link)]. The tricuspid annular plane systolic excursion (TAPSE) was obtained by placing the M-mode cursor laterally to the tricuspid annulus. We estimated the PASP by continuous Doppler at tricuspid valve level, and PASP was obtained as the sum of the mean of 4 peak velocity of tricuspid regurgitation and the estimate of right atrial pressure based on ICV diameter and collapsibility. ICV dimension and collapse was calculated by subcostal view measuring in m-mode the internal vessel diameter soon before right atrium (RA) entrance during both expiration and inspiration. When the diameter reduction in inspiration was less than 50%, we added 10 mmHg to the TR velocity [18 (link)].
Full text: Click here
Publication 2023
4-S-(propionic acid)sulfidocyclophosphamide Atrial Fibrillation Atrium, Right Blood Vessel Cardiologists Deceleration Diastole Echocardiography Heart Heart Atrium Inhalation Movement Myocardium Patients Physicians Shock Systole Tissues Tricuspid Valve Insufficiency Ultrasonography, Doppler, Pulsed Valves, Tricuspid

Top products related to «4-S-(propionic acid)sulfidocyclophosphamide»

Sourced in United States, Norway, United Kingdom, Japan, France, Canada, Germany, Belgium
The Vivid 7 is a high-performance ultrasound system designed for cardiovascular and general imaging applications. It features advanced imaging technologies and versatile capabilities to support comprehensive diagnostic assessments.
Sourced in United States
PageBlue solution is a ready-to-use protein staining solution used in gel electrophoresis to detect and visualize proteins in polyacrylamide gels.
Sourced in United Kingdom, United States, France, Germany, Japan, China, Netherlands
The Zetasizer Nano ZS90 is a dynamic light scattering (DLS) instrument designed for the measurement of particle size and zeta potential. It utilizes a 633 nm laser and a detection angle of 90 degrees to analyze the Brownian motion of particles in a sample. The instrument can measure particle sizes ranging from 0.3 nm to 10 μm and zeta potential values from -500 mV to +500 mV.
Sourced in United States, Japan, United Kingdom
The 2414 refractive index detector is a laboratory instrument designed to measure the refractive index of liquids or dissolved substances. It provides precise and accurate measurements to support various analytical applications.
Sourced in United States, United Kingdom, China, Germany, Canada, Japan, France, Australia, Italy, Switzerland, Spain, Brazil, Belgium, Netherlands, Ireland, Singapore, Poland, Macao, India, Sweden, Denmark, Austria, Argentina, Israel, Lithuania
Trypsin is a proteolytic enzyme that hydrolyzes peptide bonds in proteins. It is commonly used in cell biology and molecular biology applications to facilitate cell detachment and dissociation.
The 1525 chromatograph is a laboratory instrument designed for the separation and analysis of chemical compounds. It functions as a key component in various analytical procedures, providing users with the necessary capabilities to perform complex separations and quantitative measurements.
Sourced in United States
PureCol® Type I Collagen Solution is a sterile, highly purified Type I collagen solution derived from bovine sources. It is designed for use in cell culture, tissue engineering, and other research applications requiring a high-quality collagen material.
Sourced in United States, Germany, United Kingdom, Italy, Brazil
The PureLink Genomic DNA Kit is a laboratory equipment product designed for the rapid and efficient extraction and purification of genomic DNA from a variety of sample types. It utilizes a spin column-based method to isolate high-quality DNA that can be used in various downstream applications.
Sourced in United States, United Kingdom, Germany, China, Lithuania
The MEGAscript T7 kit is a powerful tool for in vitro transcription of RNA. It utilizes the T7 RNA polymerase to efficiently generate large quantities of RNA from DNA templates. The kit provides the necessary reagents and instructions to perform this process.
Sourced in Germany, United States
Potassium hydroxide pellets are a chemical compound with the formula KOH. They are a white, crystalline solid that is highly soluble in water. Potassium hydroxide pellets are primarily used as a strong base and are commonly employed in various industrial and laboratory applications.

More about "4-S-(propionic acid)sulfidocyclophosphamide"

4-S-(Propionic Acid)Sulfidocyclophosphamide, also known as 4-PS, is a powerful alkylating agent and antimetabolite chemotherapeutic compound.
It is commonly used in the treatment of various cancers, including leukemia and lymphoma.
This compound works by disrupting DNA replication and cell division, ultimately leading to cell death.
Researchers studying 4-PS must carefully consider their research protocols and product selection to optimize the efficacy and reproducibility of their experiments.
PubCompare.ai's AI-driven platform can assist researchers in identifying the best products and protocols from literature, preprints, and patents, enhancing the accuracy and reliability of their 4-PS research.
To further support 4-PS studies, researchers may utilize tools like Vivid 7, PageBlue solution, Zetasizer Nano ZS90, 2414 refractive index detector, Trypsin, 1525 chromatogrph, PureCol® Type I Collagen Solution, PureLink Genomic DNA Kit, MEGAscript T7 kit, and Potassium hydroxide pellets.
These technologies can provide valuable insights and data to complement the investigation of this potent chemotherapeutic compound.
By leveraging the power of AI and the right tools, researchers can unlock new possibilities in their 4-PS research, leading to breakthroughs in cancer treatment and improving patient outcomes.
Experience the difference that PubCompare.ai can make in your 4-PS studies today!